51 related articles for article (PubMed ID: 8555648)
1. The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells.
Cameron MR; Caudle MR; Sullivan WR; Peluso JJ; Wimalasena J
Oncol Res; 1995; 7(3-4):145-56. PubMed ID: 8555648
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways.
Wang TH; Chan YH; Chen CW; Kung WH; Lee YS; Wang ST; Chang TC; Wang HS
Oncogene; 2006 Aug; 25(35):4857-66. PubMed ID: 16547493
[TBL] [Abstract][Full Text] [Related]
5. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.
Belotti D; Rieppi M; Nicoletti MI; Casazza AM; Fojo T; Taraboletti G; Giavazzi R
Clin Cancer Res; 1996 Oct; 2(10):1725-30. PubMed ID: 9816123
[TBL] [Abstract][Full Text] [Related]
7. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
Law KS; Chen HC; Liao SK
Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
[TBL] [Abstract][Full Text] [Related]
8. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro.
Jaime J; Pagé M
Anticancer Res; 2001; 21(2A):1119-28. PubMed ID: 11396150
[TBL] [Abstract][Full Text] [Related]
10. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
12. The range of optimal concentration and mechanisms of paclitaxel in radio-enhancement in gastrointestinal cancer cell lines.
Toiyama Y; Inoue Y; Hiro J; Ojima E; Watanabe H; Narita Y; Hosono A; Miki C; Kusunoki M
Cancer Chemother Pharmacol; 2007 May; 59(6):733-42. PubMed ID: 16957932
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.
Gooch JL; Lee AV; Yee D
Cancer Res; 1998 Sep; 58(18):4199-205. PubMed ID: 9751635
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.
Au JL; Li D; Gan Y; Gao X; Johnson AL; Johnston J; Millenbaugh NJ; Jang SH; Kuh HJ; Chen CT; Wientjes MG
Cancer Res; 1998 May; 58(10):2141-8. PubMed ID: 9605758
[TBL] [Abstract][Full Text] [Related]
16. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.
Paulsen T; Marth C; Kaern J; Nustad K; Kristensen GB; Tropé C
Gynecol Oncol; 2000 Mar; 76(3):326-30. PubMed ID: 10684705
[TBL] [Abstract][Full Text] [Related]
17. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
18. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro.
Michalakis J; Georgatos SD; de Bree E; Polioudaki H; Romanos J; Georgoulias V; Tsiftsis DD; Theodoropoulos PA
Ann Surg Oncol; 2007 Mar; 14(3):1220-8. PubMed ID: 17206477
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer cell lines are sensitive to paclitaxel.
Rantanen V; Grénman S; Kulmala J; Grénman R
Anticancer Res; 1996; 16(1):475-9. PubMed ID: 8615657
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
